BioNTech (BNTX) Stock Jumps 22% Following Moderna’s Cancer Vaccine Breakthrough

Key Takeaways

• Shares of BioNTech climbed 22% to reach $113.12, marking the company’s strongest daily performance since April 2023
• The surge followed encouraging Phase 3 data from Moderna and Merck’s customized cancer treatment, intismeran autogene, used with Keytruda
• Leerink Partners’ Daina Graybosch warns the momentum will probably dissipate, noting limited relevance to BioNTech’s situation
• BioNTech’s cancer vaccine development has lagged behind Moderna’s timeline, with a significant candidate halted in late 2025
• The biotech firm is navigating a founder departure and declining revenue in the post-Covid era

Shares of BioNTech experienced a dramatic 22% climb on Wednesday, closing at $113.12 and recording the company’s most significant one-day advance in nearly two years. The surge followed the announcement of successful Phase 3 clinical trial results from Moderna and Merck regarding their individualized cancer treatment.

BioNTech SE, BNTX

The clinical study, designated INTerpath-001, demonstrated that intismeran autogene when paired with Merck’s checkpoint inhibitor Keytruda delivered superior outcomes in preventing melanoma from returning compared to Keytruda administered as a standalone therapy. Market response was substantial, with Moderna shares nearly tripling in value and Merck climbing more than 12%.

The positive sentiment spread across the vaccine industry. Novavax shares rose 11%, as investors broadly embraced companies in the immunotherapy space following the encouraging clinical data.

However, Wall Street analysts from Leerink Partners were quick to temper expectations regarding BNTX shares specifically. Daina Graybosch, an analyst at the firm, cautioned that the stock’s advance will likely “fade as investors absorb the poor read-through.”

Her assessment is clear-cut: the clinical achievement belongs squarely to Moderna and Merck, with minimal implications for BioNTech. Though BioNTech operates its own mRNA-based cancer immunotherapy programs, progress has lagged behind competitors.

Slowing Development Timeline

BioNTech’s oncology vaccine initiatives center on the iNeST technology platform, created in partnership with Genentech, a Roche subsidiary. This approach focuses on solid tumor malignancies through individualized vaccines tailored to specific genetic mutations.

The development trajectory has encountered obstacles. Late in 2025, BioNTech halted work on BNT111, a candidate targeting advanced treatment-resistant melanoma, following Phase 2 evaluation in combination with Regeneron’s immunotherapy Libtayo.

According to Leerink’s analysis, BioNTech’s prospects of emerging as a frontrunner in cancer immunotherapy have diminished significantly, to the extent that such potential no longer factors into current valuations.

Goldman Sachs’ Asad Haider recently highlighted pumitamig as a more promising asset within BioNTech’s portfolio, describing its non-small cell lung cancer results as “encouraging,” while acknowledging a competing therapy has achieved more advanced development stages.

Management Transition and Financial Challenges

Compounding pipeline concerns, BioNTech is managing a significant leadership transition. The company’s founding couple plans to depart before year-end to establish a separate biotechnology venture. BioNTech has arranged to provide mRNA platform access to this new entity in exchange for equity participation, developmental milestone fees, and product royalties.

Financially, challenges persist. Recent second-quarter results revealed continued heavy reliance on Covid-19 vaccine sales, which remain on a downward trajectory. Management’s full-year revenue projections disappointed Wall Street forecasts.

By contrast, Pfizer, BioNTech’s Covid vaccine collaborator, has demonstrated more effective navigation through the post-pandemic business environment.

Analyst focus appears to be gradually moving away from BioNTech’s cancer vaccine initiatives toward other components of its broader oncology development portfolio.

The company’s annual revenue outlook underperformed analyst consensus estimates based on its latest quarterly financial disclosures.

The post BioNTech (BNTX) Stock Jumps 22% Following Moderna’s Cancer Vaccine Breakthrough appeared first on Blockonomi.